ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination

(2021) Erwan Vo Quang et al.   LIVER INTERNATIONAL

Elevated expression of ASF1B correlates with poor prognosis in human lung adenocarcinoma

(2021) Zhenxing Feng et al.   Personalized Medicine

Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1

(2021) Zaoqu Liu et al.   Frontiers in Oncology

Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia

(2021) Xu Han et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer

(2021) Dan Wei et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker

(2021) Xinyao Hu et al.   Cancer Medicine

Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer

(2021) Zaoqu Liu et al.   Frontiers in Immunology

ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types

(2021) Wencheng Zhang et al.   Frontiers in Oncology

Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment

(2021) Jing Ma et al.   Frontiers in Oncology

Construction of Novel lncRNA–miRNA–mRNA Network Associated With Recurrence and Identification of Immune-Related Potential Regulatory Axis in Hepatocellular Carcinoma

(2021) Tian Zhan et al.   Frontiers in Oncology

Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma

(2021) Zaoqu Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Inhibition of CDK9 activity compromises global splicing in prostate cancer cells

(2021) Qiang Hu et al.   RNA Biology

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epidemiology and surveillance for hepatocellular carcinoma: New trends

(2020) Amit G. Singal et al.   JOURNAL OF HEPATOLOGY

Molecular therapies for HCC: Looking outside the box

(2020) Sandrine Faivre et al.   JOURNAL OF HEPATOLOGY

Advances in molecular classification and precision oncology in hepatocellular carcinoma

(2020) Sandra Rebouissou et al.   JOURNAL OF HEPATOLOGY

Inhibition of cyclinB1 Suppressed the Proliferation, Invasion, and Epithelial Mesenchymal Transition of Hepatocellular Carcinoma Cells and Enhanced the Sensitivity to TRAIL-Induced Apoptosis

(2020) Shuai Lv et al.   OncoTargets and Therapy

Modern therapeutic approaches for the treatment of malignant liver tumours

(2020) Henrik Petrowsky et al.   Nature Reviews Gastroenterology & Hepatology

Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma

(2020) Anjana Pillai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Comprehensive analysis of ubiquitin‐specific protease 1 reveals its importance in hepatocellular carcinoma

(2020) Yalei Zhao et al.   CELL PROLIFERATION

ASF1B promotes cervical cancer progression through stabilization of CDK9

(2020) Xinjian Liu et al.   Cell Death & Disease

Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives

(2020) Yasi Pan et al.   Biomedicines

Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma

(2020) Junfeng Wang et al.   JOURNAL OF HEPATOLOGY

Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy

(2020) Albert Carrion et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Goals and targets for personalized therapy for HCC

(2019) Thomas Couri et al.   Hepatology International

Downregulation of G2/mitotic-specific cyclinB1 triggers autophagy via AMPK-ULK1-dependent signal pathway in nasopharyngeal carcinoma cells

(2019) Xianhe Xie et al.   Cell Death & Disease

Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma

(2019) Zhou Jiangqiao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma

(2019) Yu-Yun Shao et al.   Cancers

Dynamic Alterations of Plasma Metabolites in the Progression of Liver Regeneration after Partial Hepatectomy

(2019) Yalei Zhao et al.   JOURNAL OF PROTEOME RESEARCH

Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer

(2018) Guangye Han et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Molecular therapies and precision medicine for hepatocellular carcinoma

(2018) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

(2018) Renumathy Dhanasekaran et al.   GASTROENTEROLOGY

CDK9: A key player in cancer and other diseases

(2017) Lia Carolina Franco et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Prognostic implication of morphology, cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts

(2014) Siok-Bian Ng et al.   Orphanet Journal of Rare Diseases

PCNA: a silent housekeeper or a potential therapeutic target?

(2014) Shao-Chun Wang   TRENDS IN PHARMACOLOGICAL SCIENCES

Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer

(2010) Armelle Corpet et al.   EMBO JOURNAL

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES